NCT06235541 2025-07-17
A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors
Genome & Company
Phase 1 Withdrawn
Genome & Company
EMD Serono
Pfizer
Bristol-Myers Squibb
GlaxoSmithKline
University of Southern California
Dartmouth-Hitchcock Medical Center